Gapping up
In reaction to strong earnings/guidance: LGCY +26.5%, EPE +18.8%, WTW+14.2%, ZNGA +13%, LHCG +9.2%, AVID +8.9%, GSS +8.3%, ARRS +8.1%, DNR+8%, GPL +7%, HDSN +6.9%, BNFT +6.7%, NRG +6.6%, QRVO +6.3%, NEWT +6%,SZYM +5.9%, KHC +5.7%, ETE +5.3%, BABA +4.9%, AUY +4.7%, CECO +4.4%, +4.4%, AXGN +4.3%, TSLA +4%, CLR +4%, ORA +3.9%, MTW +3.9%, WBMD+3.8%, CSOD +3.5%, MRO +3.4%, KND +3.4%, BT +3.4%, DOOR +3.2%, RIG+3.1%, AREX +2.8%, CF +2.8%, NICE +2.8%, GIL +2.7%, (Ennis accepts a superior offer to sell its apparel division to Gildan Activewear (GIL) for $110 mln in cash), TASR +2.6%, TASR +2.6%, CBMX +2.5%, TDC +2.5%, FIG +2.5%, GORO+2.4%, RLYP +2.2%, TWO +2.2%, PAGP +2.1%, CB +1.9%, CATO +1.9%, ALDW+1.6%, STOR +1.5%, MBLY +1.3%, AG +1.3%, MCK +1.2%, CENT +1.2%, OREX+1.1%, LXP +1.1%, OXY +1%, EQIX +0.9%, CBPO +0.8%, JONE +0.7%, WFM+0.5%, HL +0.5%
M&A news: ZPIN +9.6% (receives non-binding proposal letter to be taken private), TPUB +4.4% (Tribune Publishing Board sends letter rejecting Gannett's (GCI) acquisition proposal at $12.25/share in cash, also reported earnings), BMI+2.2% (confirms it is exploring on a preliminary basis various options to enhance shareholder value)
Other news: SYNC +144.7% (awarded contract from AT&T, also reported earnings), FCEL +21% (FuelCell Energy and Exxon (XOM) announce an agreement to pursue novel technology in power plant carbon dioxide capture through a new application of carbonate fuel cells), CNAT +16.2% (Conatus Pharma announces 'positive' top-line results from the three-month, open-label second stage ofits multicenter Phase 2 clinical trial of emricasan in patients with liver cirrhosis ),UNXL +11.7% (announces the addition of a new customer with design wins for two new notebooks featuring itsXTouch and Diamond Guard technologies), SGYP+7.9% (commences ~29.95 mln registered direct common stock offering with certain investors at $3.00/share), RWLK +6.6% (announces that the US Dept of VA has purchased an additional 20 ReWalk Personal Systems to 'support initiation' of their national clinical trial ), YHOO +3.9% (trading higher in sympathy with BABA), GM +1.7% (Greenlight's Einhorn reiterates positive stance on GM at Ira Sohn), MYL +1.1% (announces the U.S. launch of Hydralazine Hydrochloride Injection), VRX +1.1% (Valeant Pharma and IBM (IBM) announce a collaboration to develop an iPhone/iPad app to assist surgeons who perform cataract surgery)
Analyst comments: BHP +1.7% (upgraded to Equal Weight from Underweight at Barclays), XL +1.1% (upgraded to Hold from Sell at Deutsche Bank)
In reaction to strong earnings/guidance: LGCY +26.5%, EPE +18.8%, WTW+14.2%, ZNGA +13%, LHCG +9.2%, AVID +8.9%, GSS +8.3%, ARRS +8.1%, DNR+8%, GPL +7%, HDSN +6.9%, BNFT +6.7%, NRG +6.6%, QRVO +6.3%, NEWT +6%,SZYM +5.9%, KHC +5.7%, ETE +5.3%, BABA +4.9%, AUY +4.7%, CECO +4.4%, +4.4%, AXGN +4.3%, TSLA +4%, CLR +4%, ORA +3.9%, MTW +3.9%, WBMD+3.8%, CSOD +3.5%, MRO +3.4%, KND +3.4%, BT +3.4%, DOOR +3.2%, RIG+3.1%, AREX +2.8%, CF +2.8%, NICE +2.8%, GIL +2.7%, (Ennis accepts a superior offer to sell its apparel division to Gildan Activewear (GIL) for $110 mln in cash), TASR +2.6%, TASR +2.6%, CBMX +2.5%, TDC +2.5%, FIG +2.5%, GORO+2.4%, RLYP +2.2%, TWO +2.2%, PAGP +2.1%, CB +1.9%, CATO +1.9%, ALDW+1.6%, STOR +1.5%, MBLY +1.3%, AG +1.3%, MCK +1.2%, CENT +1.2%, OREX+1.1%, LXP +1.1%, OXY +1%, EQIX +0.9%, CBPO +0.8%, JONE +0.7%, WFM+0.5%, HL +0.5%
M&A news: ZPIN +9.6% (receives non-binding proposal letter to be taken private), TPUB +4.4% (Tribune Publishing Board sends letter rejecting Gannett's (GCI) acquisition proposal at $12.25/share in cash, also reported earnings), BMI+2.2% (confirms it is exploring on a preliminary basis various options to enhance shareholder value)
Other news: SYNC +144.7% (awarded contract from AT&T, also reported earnings), FCEL +21% (FuelCell Energy and Exxon (XOM) announce an agreement to pursue novel technology in power plant carbon dioxide capture through a new application of carbonate fuel cells), CNAT +16.2% (Conatus Pharma announces 'positive' top-line results from the three-month, open-label second stage ofits multicenter Phase 2 clinical trial of emricasan in patients with liver cirrhosis ),UNXL +11.7% (announces the addition of a new customer with design wins for two new notebooks featuring itsXTouch and Diamond Guard technologies), SGYP+7.9% (commences ~29.95 mln registered direct common stock offering with certain investors at $3.00/share), RWLK +6.6% (announces that the US Dept of VA has purchased an additional 20 ReWalk Personal Systems to 'support initiation' of their national clinical trial ), YHOO +3.9% (trading higher in sympathy with BABA), GM +1.7% (Greenlight's Einhorn reiterates positive stance on GM at Ira Sohn), MYL +1.1% (announces the U.S. launch of Hydralazine Hydrochloride Injection), VRX +1.1% (Valeant Pharma and IBM (IBM) announce a collaboration to develop an iPhone/iPad app to assist surgeons who perform cataract surgery)
Analyst comments: BHP +1.7% (upgraded to Equal Weight from Underweight at Barclays), XL +1.1% (upgraded to Hold from Sell at Deutsche Bank)